JD Health to Launch 65 New Drugs in H1 2026, With 65% of Users From Lower-Tier Cities
JD Health, the healthcare arm of JD. com, plans to debut 65 new drugs in the first half of 2026, covering oncology, dermatology, and chronic diseases. The company said users from third-tier and below cities now account for over 65% of its total user base. It has established nearly 100,000 service points in townships and villages nationwide, achieving same-day or next-day delivery coverage of 87.1% in county-level areas.
In the first half of 2026, JD Health will cumulatively launch 65 new drugs, covering areas such as oncology, dermatology, and chronic diseases. The introduction of these new drugs enriches the platform's pharmaceutical supply in the corresponding therapeutic fields.
To date, users from third-tier and below cities account for more than 65% of JD Health's total user base. The company has deployed nearly 100,000 service points in townships and villages nationwide, with same-day or next-day delivery coverage reaching 87.1% in county-level areas.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmacy Retail, with intensity 70/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.